Different underlying causes and mechanisms may sustain several pain syndromes in hematological malignant patients. Pain may be due to disease itself, to disease-related complications, to ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The program provides intensive exposure to the breadth of hematology and oncology topics, including virtually every type of solid tumor, the spectrum of anemias, coagulation and thrombotic diatheses, ...

More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.Researchers identified several risk factors, including older age, ...

Hematology Research Unit Helsinki (HRUH) is a translational research group, which aims to understand the pathobiology of malignant blood diseases (such as leukemia) and related autoimmune disorders, ...

Welcome to the Division of Hematology and Oncology. Our division is a growing division that provides superb clinical care for patient across the spectrum of benign hematologic disorders, malignant ...

Table 1. Description and outline of the advantages and disadvantages of the most commonly used pain assessment tools. Pain assessment tool Description Advantages Disadvantages Verbal rating ...

Hematology and Oncology board certification. We aspire to cultivate a culture of well-being, collegiality, and positivity to promote academic pursuit. This broad-based educational opportunity explores ...

Geyer Jr., M.D., professor in the Division of Malignant Hematology and Medical Oncology at the Pitt School of Medicine, UPMC Hillman and UPMC Magee-Womens Hospital. “We continued to follow ...